Pfizer’s LILRB1 x LILRB2 bispecific is about to enter the clinic.

Five years after AbbVie pulled the plug on rova-T, DLL3 comes under the spotlight again.

Merck turns to China for a molecule against one of biopharma’s most extensively studied antigens.

But there are no hard facts, and a Ligand obligation clouds future licensing economics.

Keyvibe-008 is halted for futility, an outcome that might have been foreseen in 2022.

Following its odronextamab knockback, Regeneron now faces a delay to linvoseltamab.